Monocenter, Open-Label, Randomized Study to Determine the Ovulation Inhibitory Effect of the Combined Oral Contraceptive SH T04769G and SH D00659AF (0.03 mg Ethinylestradiol and 2.0 mg Dienogest), Applied for Two Treatment Cycles to 60 Healthy Female Volunteers.
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2013
At a glance
- Drugs Ethinylestradiol/dienogest (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Bayer
- 28 Sep 2008 Trial identifier 91539 added as reported by CT.gov
- 12 Jun 2007 New trial record.